US pharma giant Pfizer (NYSE: PFE) has presented its financial results for the fourth quarter and full year of 2023.
Known as pharma's biggest company, Pfizer took a step back towards the pack in 2023 as the loss of sales from its COVID-19 products Comirnaty and Paxlovid (nirmatrelvir/ritonavir) dented its revenue.
The firm's total revenue figure for the fourth quarter met analysts' expectations, at $14.25 billion, a 41% decline on the same period in 2022, as the US government returned fewer doses of Paxlovid than feared.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze